Emerging biomarkers for CD3×CD20 bispecific antibodies in lymphoma

2.

Sun

LL

,

Ellerman

D

,

Mathieu

M

, et al.

Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

.

Sci Transl Med

.

2015

;

7

(

287

):

287ra70

.

3.

Bartlett

NL

,

Assouline

S

,

Giri

P

, et al.

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

.

Blood Adv

.

2023

;

7

(

17

):

4926

-

4935

.

4.

Dickinson

MJ

,

Carlo-Stella

C

,

Morschhauser

F

, et al.

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

.

N Engl J Med

.

2022

;

387

(

24

):

2220

-

2231

.

5.

Bacac

M

,

Colombetti

S

,

Herter

S

, et al.

CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies

.

Clin Cancer Res

.

2018

;

24

(

19

):

4785

-

4797

.

6.

Morschhauser

F

,

Carlo-Stella

C

,

Dickinson

M

, et al.

Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) follicular lymphoma (FL) [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

128

.

7.

Linton

KM

,

Vitolo

U

,

Jurczak

W

, et al.

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

.

Lancet Haematol

.

2024

;

11

(

8

):

e593

-

e605

.

8.

Thieblemont

C

,

Phillips

T

,

Ghesquieres

H

, et al.

Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-Eegaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial

.

J Clin Oncol

.

2023

;

41

(

12

):

2238

-

2247

.

9.

Engelberts

PJ

,

Hiemstra

IH

,

de Jong

B

, et al.

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

.

eBioMedicine

.

2020

;

52

:

102625

.

10.

Ayyappan

S

,

Kim

WS

,

Kim

TM

, et al.

Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

436

.

11.

Bannerji

R

,

Arnason

JE

,

Advani

RH

, et al.

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

.

Lancet Haematol

.

2022

;

9

(

5

):

e327

-

e339

.

12.

Smith

EJ

,

Olson

K

,

Haber

LJ

, et al.

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys

.

Sci Rep

.

2015

;

5

(

1

):

17943

.

13.

Kim

TM

,

Taszner

M

,

Novelli

S

, et al.

Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma

.

Ann Oncol

.

2024

;

35

(

11

):

1039

-

1047

.

14.

Iacoboni

G

,

Serna

A

,

Navarro Garces

V

, et al.

Impact of prior bendamustine exposure on bispecific antibody treatment outcomes for patients with B-cell lymphoma [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

310

.

15.

Olszewski

AJ

,

Phillips

TJ

,

Hoffmann

MS

, et al.

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

.

Blood Adv

.

2023

;

7

(

20

):

6055

-

6065

.

16.

Budde

LE

,

Olszewski

AJ

,

Assouline

S

, et al.

Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial

.

Nat Med

.

2024

;

30

(

1

):

229

-

239

.

17.

Hutchings

M

,

Carlo-Stella

C

,

Morschhauser

F

, et al.

Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

433

.

18.

Schuster

SJ

,

Huw

LY

,

Bolen

CR

, et al.

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

.

Blood

.

2024

;

143

(

9

):

822

-

832

.

19.

Melody

M

,

Grover

N

,

Franco

S

, et al.

Efficacy, toxicity, and predictors of outcomes with CD3-CD20 bi-specific antibodies post CAR T-cell failure for aggressive B-cell lymphoma [abstract]

.

Blood

.

2024

;

144

(

suppl 1

):

473

.

20.

Bröske

AME

,

Korfi

K

,

Belousov

A

, et al.

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma

.

Blood Adv

.

2022

;

6

(

3

):

1025

-

1037

.

21.

Iraola-Truchuelo

J

,

Iacoboni

G

,

Palomo

L

, et al.

Resistance mechanisms impacting bispecific antibody (BsAbs) and chimeric antigen receptor (CAR) T-cell therapy outcomes in large B cell lymphoma (LBCL) patients [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

1635

.

22.

Thieblemont

C

,

Karimi

YH

,

Ghesquieres

H

, et al.

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

.

Leukemia

.

2024

;

38

(

12

):

2653

-

2662

.

23.

Duell

J

,

Leipold

AM

,

Appenzeller

S

, et al.

Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy

.

Blood

.

2024

;

143

(

8

):

685

-

696

.

24.

Brouwer-Visser

J

,

Fiaschi

N

,

Deering

RP

, et al.

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

.

J Immunother Cancer

.

2024

;

12

(

3

):

e008338

.

25.

Piccione

EC

,

Belousov

A

,

Hamidi

H

, et al.

Immune correlates of response to glofitamab: biomarker findings from a pivotal phase II expansion study in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

.

HemaSphere

.

2022

;

6

(

suppl

):

1096

-

1097

.

26.

Zhou

Z

,

Sehn

LH

,

Rademaker

AW

, et al.

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

.

Blood

.

2014

;

123

(

6

):

837

-

842

.

27.

Buske

C

,

Hoster

E

,

Dreyling

M

,

Hasford

J

,

Unterhalt

M

,

Hiddemann

W

.

The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome

.

Blood

.

2006

;

108

(

5

):

1504

-

1508

.

28.

Matasar

M

,

Bartlett

NL

,

Sehn

LH

, et al.

Mosunetuzumab is efficacious and well tolerated in patients aged <65 and ≥65 with relapsed/refractory follicular lymphoma and ≥2 prior therapies: subgroup analysis of a pivotal phase II study

.

HemaSphere

.

2022

;

6

(

suppl

):

1016

-

1017

.

29.

Brody

J

,

Joergensen

JM

,

Belada

D

, et al.

Epcoritamab SC + GemOx Leads to high complete metabolic response rates in patients with relapsed/refractory diffuse large B-cell lymphoma ineligible for autologous stem cell transplant: updated results from Epcore NHL-2 [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

3092

.

30.

Olszewski

AJ

,

Budde

LE

,

Chavez

J

, et al.

Mosunetuzumab with polatuzumab vedotin is effective and has a manageable safety profile in patients aged <65 and ≥65 years with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and ≥1 prior therapy: subgroup analysis of a phase Ib/II study [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

3757

-

3759

.

31.

Olszewski

AJ

,

Avigdor

A

,

Babu

S

, et al.

Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma [abstract]

.

Blood

.

2020

;

136

(

suppl 1

):

43

-

45

.

32.

Shumilov

E

,

Wurm-Kuczera

R

,

Vucinic

V

, et al.

Time of CAR-T failure is a strong predictor of outcome for bispecific antibody therapy in relapsed/refractory large B-cell lymphoma [abstract]

.

Blood

.

2024

;

144

(

suppl 1

):

114

.

33.

Haydu

JE

,

Abramson

JS

.

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas

.

Blood Adv

.

2024

;

8

(

17

):

4700

-

4710

.

34.

Crochet

G

,

Iacoboni

G

,

Couturier

A

, et al.

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

.

Blood

.

2024

;

144

(

3

):

334

-

338

.

35.

Kim

J

,

Cho

J

,

Lee

MH

,

Yoon

SE

,

Kim

WS

,

Kim

SJ

.

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis

.

Blood

.

2024

;

144

(

6

):

629

-

638

.

36.

Phillips

TJ

,

Clausen

MR

,

Jurczak

W

, et al.

Prior bendamustine (benda) exposure did not impact clinical outcomes and decreased CD4+ but not CD8+ T-cells in patients with diffuse large B-cell lymphoma (DLBCL) treated with the bispecific antibody epcoritamab (epcor) [abstract]

.

Blood

.

2024

;

144

(

suppl 1

):

3115

.

37.

Iacoboni

G

,

Kyvsgaard

ER

,

Navarro Garces

V

, et al.

Impact of prior bendamustine exposure on bispecific antibody treatment outcomes in patients with relapsed/refractory follicular lymphoma [abstract]

.

Blood

.

2024

;

144

(

suppl 1

):

3009

.

38.

Ang

Z

,

Paruzzo

L

,

Hayer

KE

, et al.

Alternative splicing of its 5’-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

.

Blood

.

2023

;

142

(

20

):

1724

-

1739

.

39.

Rushton

CK

,

Arthur

SE

,

Alcaide

M

, et al.

Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma

.

Blood Adv

.

2020

;

4

(

13

):

2886

-

2898

.

40.

van der Horst

HJ

,

de Jonge

AV

,

Hiemstra

IH

, et al.

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

.

Blood Cancer J

.

2021

;

11

(

2

):

38

.

https://doi.org/10.1101/2024.07.02.24309792

41.

Falchi

L

,

Rahman

J

,

Melendez

L

, et al.

Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas

.

medRxiv

.

Preprint posted online 5 July 2024

.

42.

Hans

CP

,

Weisenburger

DD

,

Greiner

TC

, et al.

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

.

Blood

.

2004

;

103

(

1

):

275

-

282

.

43.

Scott

DW

,

Wright

GW

,

Williams

PM

, et al.

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue

.

Blood

.

2014

;

123

(

8

):

1214

-

1217

.

44.

Martínez-Laperche

C

,

Sanz-Villanueva

L

,

Díaz Crespo

FJ

, et al.

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. [published correction appears in BMC Cancer. 2022;22(1):1224]

.

BMC Cancer

.

2022

;

22

(

1

):

982

.

45.

Wherry

EJ

,

Kurachi

M

.

Molecular and cellular insights into T cell exhaustion

.

Nat Rev Immunol

.

2015

;

15

(

8

):

486

-

499

.

46.

Crespo

J

,

Sun

H

,

Welling

TH

,

Tian

Z

,

Zou

W

.

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment

.

Curr Opin Immunol

.

2013

;

25

(

2

):

214

-

221

.

47.

Philipp

N

,

Kazerani

M

,

Nicholls

A

, et al.

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

.

Blood

.

2022

;

140

(

10

):

1104

-

1118

.

48.

Blank

CU

,

Haining

WN

,

Held

W

, et al.

Defining ‘T cell exhaustion.’

.

Nat Rev Immunol

.

2019

;

19

(

11

):

665

-

674

.

49.

Truong

NTH

,

Gargett

T

,

Brown

MP

,

Ebert

LM

.

Effects of chemotherapy agents on circulating leukocyte populations: potential implications for the success of CAR-T cell therapies

.

Cancers

.

2021

;

13

(

9

):

2225

.

50.

Meermeier

EW

,

Welsh

SJ

,

Sharik

ME

, et al.

Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. [published correction appears in Blood Cancer Discov. 2022;3(1):82]

.

Blood Cancer Discov

.

2021

;

2

(

4

):

354

-

369

.

51.

van de Donk

NWCJ

,

Chari

A

,

Mateos

MV

.

Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies

.

Lancet Haematol

.

2024

;

11

(

9

):

e693

-

e707

.

52.

Friedrich

MJ

,

Neri

P

,

Kehl

N

, et al.

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

.

Cancer Cell

.

2023

;

41

(

4

):

711

-

725.e6

.